Clinical Trials Logo

Psoriasis clinical trials

View clinical trials related to Psoriasis.

Filter by:

NCT ID: NCT02949388 Completed - Clinical trials for Chronic Stable Plaque Psoriasis

Efficacy and Safety of Prurisol Administered Orally for Active Moderate to Severe Chronic Plaque Psoriasis

Start date: November 2016
Phase: Phase 2
Study type: Interventional

This study is designed as a randomized, double blind, parallel group, placebo-controlled trial to study the efficacy and safety of two oral doses of Prurisol administered twice daily for twelve weeks to subjects with moderate to severe chronic plaque psoriasis.

NCT ID: NCT02940002 Completed - Psoriasis Clinical Trials

BAY1003803 Formulation Comparison in Open Psoriasis Plaque Test

Start date: October 12, 2016
Phase: Phase 1
Study type: Interventional

To explore the efficacy and safety of four BAY1003803 formulations by means of a within subject comparison in an open Psoriasis Plaque Test

NCT ID: NCT02935582 Completed - Psoriasis Vulgaris Clinical Trials

PSOREAL - Managing PSOriasis in the REAL World

PSOREAL
Start date: January 2017
Phase:
Study type: Observational

Multinational real-life study of current psoriasis treatment strategies, topical treatment patterns and treatment outcomes of these treatments, including the newly introduced calcipotriol/betamethasone dipropionate aerosol foam fixed combination product Enstilar® (calcipotriol/betamethasone dipropionate).

NCT ID: NCT02934412 Completed - Psoriasis Clinical Trials

A Study of SHR-1314 in Healthy Subjects

Start date: August 22, 2016
Phase: Phase 1
Study type: Interventional

This is a randomized, double-blind, placebo-controlled, single dose escalating, study in 5 sequential cohorts to investigate the effect of a single s.c. injection of SHR-1314 at 5 dose levels (20mg, 40mg, 80mg, 160mg, and 240mg) in healthy subjects. Each cohort will consist of 6 subjects receiving active drug and 2 subjects receiving placebo, for a total of approximately 40 subjects dosed at one study site.

NCT ID: NCT02933866 Completed - Scalp Psoriasis Clinical Trials

Phase III Clinical Study in Patients With Mild to Severe Scalp Psoriasis

Start date: March 11, 2016
Phase: Phase 3
Study type: Interventional

A Randomized, Double-Blind, Vehicle-Controlled, Parallel-Design, Multiple-Site, Phase III Clinical Study to Evaluate the Efficacy and Safety of DSXS topical product in Patients with Mild to Severe Scalp Psoriasis

NCT ID: NCT02933528 Completed - Psoriasis Clinical Trials

Safety Study to Assess the Potential for Adrenal Suppression Following Maximal Use Treatment With DSXS

Start date: July 11, 2016
Phase: Phase 2
Study type: Interventional

An Open Label, Safety Study to Assess the Potential for Adrenal Suppression Following Maximal Use Treatment with DSXS .

NCT ID: NCT02933502 Completed - Scalp Psoriasis Clinical Trials

Safety Study in Patients With Scalp Psoriasis Suppression Following Maximal Use Treatment With Topical Product

Start date: July 11, 2016
Phase: Phase 2
Study type: Interventional

An Open-Label, Safety Study to Assess the Potential for Adrenal Suppression Following Maximal Use DSXS topical product (Taro Pharmaceuticals U.S.A., Inc.) in Patients with Moderate to SevereScalp Psoriasis

NCT ID: NCT02932878 Completed - Plaque Psoriasis Clinical Trials

An Open Label, Safety Study to Assess the Potential for Adrenal Suppression

Start date: September 2, 2016
Phase: Phase 2
Study type: Interventional

An Open Label, Safety Study to Assess the Potential for Adrenal Suppression Following Treatment with DSXS (Taro Pharmaceuticals U.S.A., Inc.) in Patients with Plaque Psoriasis

NCT ID: NCT02932462 Completed - Scalp Psoriasis Clinical Trials

Study to Evaluate Efficacy and Safety of the Topical Product in Patients With Mild to Severe Scalp Psoriasis

Start date: March 2016
Phase: Phase 3
Study type: Interventional

A Randomized Double-Blind, Vehicle-Controlled, Parallel Design, Multiple-Site, Phase III Clinical Study

NCT ID: NCT02931838 Completed - Psoriasis Clinical Trials

Study to Evaluate Effectiveness and Safety in Subjects With Moderate to Severe Psoriasis

Start date: November 15, 2016
Phase: Phase 2
Study type: Interventional

A Study to evaluate efficacy and safety in subjects with moderate to severe Psoriasis treated with BMS-986165